Articles by Anna Rose Welch

  1. The Drug Price War Hits Vaccines: Will Pfizer, GSK Give In To MSF Plea? 1/22/2015

    A new pricing war is afoot — but this time, it doesn’t involve AbbVie or Gilead Science’s HCV treatments. This week, Pfizer and GSK were both met with push-back from Doctors Without Borders (MSF) to reduce the prices of their pneumococcal vaccines to $5 per child (includes all three doses).

  2. So, You Want To Be Top Earning Healthcare CEO? Shoot For Biopharma 1/21/2015

    In 2012, Pfizer’s CEO Ian Read held the title of being the highest-paid CEO of a large pharmaceutical company, bringing roughly $26 million to the bank. His salary was $21 million more than the lowest paid large pharmaceutical CEO, NovoNordisk’s Lars Rebien Soerensen, who earned $5 million, Bloomberg reported in the spring of 2013. However, some more numbers released in June of 2014 are showing that, in 2013, Pfizer’s Read stepped aside and earned less than what several of his CEO peers in the biopharma space are making, even though Pfizer raked in $52 billion in revenue for the year.

  3. The 2015 NSCLC Immunotherapy Race Is Already Narrowing 1/20/2015

    It’s been a productive beginning of the year in the realm of immunotherapy. Recent headlines have boasted news about some major players making waves in immunotherapy — especially in the NSCLC treatment area —  which will not only benefit a large number of patients, but will also give productive players a slice of what’s expected to be a very lucrative market.  

  4. Pharma News Roundup: Amgen, Isis, Janssen, Pfizer, Novartis, And More 1/14/2015

    In recent news, stem cell research is taking the forefront as new collaborations speed up the development of CRISPR immunotherapies; Cempra is moving forward in its development of a next-generation antibiotic; and a new antisense drug could be a game-changer for autoimmune disorders of the GI tract.

  5. “Pharmaficial” Intelligence: Could Science Fiction Become A Pharma Reality? 1/14/2015

    All the buzz about wearable technology and the convergence of Google and pharma this past year has made me think about where technology is carrying our industry.

  6. FDA Launches Pharma Quality Office To Improve Drug Manufacturing, Agency Teamwork 1/14/2015

    We should expect to see even more attention lavished on pharmaceutical quality in 2015. This week, the FDA announced the launch of its long planned-for Office of Pharmaceutical Quality (OPQ).

  7. Big Pharma “Fountain Of Youth” Drug, FDA Approvals, And Other Pharma News 1/7/2015

    In the news recently, we may be closer to slowing aging with a new “Fountain of Youth” drug; two phase 3 clinical trials have reported developments in schizophrenia and female sexual disorder; and the FDA’s 2014 drug approval record has turned some heads.

  8. Merck Snaps Up Cubist: Will 2015 Be The Antibiotics Renaissance? 1/7/2015

    2014 was a big year for acquisitions. However, two other 2014 acquisitions suggest to me that Big Pharma might be planning to tackle an increasingly urgent unmet health need in 2015.

  9. Has AbbVie Started A Hep C Drug Pricing Revolution? 1/7/2015

    Right before the holidays, the FDA gave a nod to Viekira Pak, a new AbbVie drug cocktail credited with curing over 90 percent of those with genotype 1 hep C. Overall, it was a considerable year for HCV treatments. . 2014 was also the year of the “Great Pricing Wars.” 

  10. Will BRICS Have Answers To The HIV Vaccine Search? 1/7/2015

    At the beginning of December, Russia announced it was pushing not just one, but three new HIV vaccines into clinical trials. But Russia is not the only country searching for a successful HIV vaccine as we venture into 2015.